跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
达泽优 - NMPA Drug Approval Details
Approvals
/
NMPA
/
Lanadelumab Injection
Approved
生物制品
Lanadelumab Injection
Takeda Pharmaceuticals U.S.A., Inc.
🇨🇳 National Medical Products Administration
Approval Date
Dec 2, 2020
Approval ID
887z8d9V2Ey
Company
Takeda Pharmaceuticals U.S.A., Inc.
Type
生物制品
Approval Details
Approval Id
887z8d9V2Ey
Approval Number
国药准字SJ20200025
Generic Name
拉那利尤单抗注射液
Generic Name En
Lanadelumab Injection
Trade Name
达泽优
Drug Type
生物制品
Dosage Form
注射剂
Strength
300mg/2ml(150mg/ml)
Reg Date
2020-12-02
Expired Date
2025-12-01
Company Name
Takeda Pharmaceuticals U.S.A., Inc.
Production Company Name
Catalent Indiana, LLC
Company Detail Path
/organization/takeda-pharmaceuticals-u-s-a-inc
Production Company Detail Path
/organization/catalent-indiana-llc-bloomington-indiana-united-states
Approved
Quick Info
Agency
NMPA
Country
🇨🇳
Approval Date
Dec 2, 2020
Approval ID
887z8d9V2Ey
Type
生物制品
Back to NMPA Approvals